Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Myriad Genetics, Inc. (MYGN)
USD5.87
+0.01 (+0.17%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
322 North 2200 West 84116
Salt Lake City, UT, US
Salt Lake City, UT, US
CEO
Samraat S Raha
Website
myriad.com
IPO
1995-10-06
CIK 899923 ISIN US62855J1043
Also trades on
Deutsche Börse · MYD.DE (EUR)
London Stock Exchange · 0K3W.L (USD)
NASDAQ Global Select · MYGN (USD)
Description
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.87
+0.01 (+0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.64
Float Shares
87.12M
Free Float %
93.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.33% | -1.45% | -11.33% | -9.35% | -35.91% | -33.82% | -0.97% | -78.37% | -84.13% | -88.35% | -24.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (36 ratings, all time)
Hold
Price Targets & DCF
Current price
5.87
Low
6.00
+2.2%
Consensus
6.00
+2.2%
Median
6.00
+2.2%
High
6.00
+2.2%
Ratings Trend (MoM)
18% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 1 | 0 |
| Hold | 7 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
6.00
+2.2%
|
| Last Year | 2 |
7.00
+19.3%
|
| All Time | 17 |
20.29
+245.7%
|
Quality scores
Altman Z-Score
-1.88
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-1.6% Q1'26: +2.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-180.9% Q1'26: -32,627.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-42.1% Q1'26: -10.5% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-46.7% Q1'26: -15.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-89.8% Q1'26: -28.3% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+3.0% Q1'26: +2.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.63× Q1'26: -3.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 4 EPS Ana. |
Dec 2028 7 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
402.08M
est: 408.40M (-1.5%)
|
496.01M
est: 508.65M (-2.5%)
|
613.17M
est: 556.82M (+10.1%)
|
778.22M
est: 715.04M (+8.8%)
|
723.10M
est: 720.57M (+0.4%)
|
753.80M
est: 755.59M (-0.2%)
|
771.40M
est: 764.81M (+0.9%)
|
772.60M
est: 773.60M (-0.1%)
|
851.10M
est: 857.38M (-0.7%)
|
557.00M
est: 639.35M (-12.9%)
|
638.60M
est: 639.35M (-0.1%)
|
690.60M
est: 691.23M (-0.1%)
|
678.40M
est: 670.07M (+1.2%)
|
753.20M
est: 802.20M (-6.1%)
|
837.60M
est: 838.87M (-0.2%)
|
824.50M
est: 822.22M (+0.3%)
|
864.69M
863.14M – 866.22M
+5.2% YoY
|
911.03M
906.90M – 915.16M
+5.4% YoY
|
964.16M
959.94M – 968.38M
+5.8% YoY
|
1.03B
1.02B – 1.04B
+7.1% YoY
|
1.04B
1.03B – 1.05B
+0.3% YoY
|
| EBITDA |
158.13M
est: 161.10M (-1.8%)
|
180.32M
est: 196.00M (-8.0%)
|
228.00M
est: 207.66M (+9.8%)
|
274.44M
est: 179.41M (+53.0%)
|
159.20M
est: 172.35M (-7.6%)
|
193.50M
est: 131.45M (+47.2%)
|
96.40M
est: 135.96M (-29.1%)
|
113.30M
est: 86.94M (+30.3%)
|
85.00M
est: 47.56M (+78.7%)
|
-123.40M
est: -1.11B (+88.9%)
|
-140.50M
est: -1.11B (+87.4%)
|
12.30M
est: 14.74M (-16.5%)
|
-84.70M
est: 16.02M (-628.7%)
|
-197.40M
est: -135.01M (-46.2%)
|
-59.50M
est: -141.18M (+57.9%)
|
-330.90M
est: -138.38M (-139.1%)
|
-145.53M
-145.78M – -145.27M
-5.2% YoY
|
-153.33M
-154.02M – -152.63M
-5.4% YoY
|
-162.27M
-162.98M – -161.56M
-5.8% YoY
|
-173.80M
-175.77M – -172.33M
-7.1% YoY
|
-174.28M
-176.26M – -172.81M
-0.3% YoY
|
| EBIT |
—
est: 154.65M (-100.0%)
|
—
est: 182.75M (-100.0%)
|
—
est: 197.85M (-100.0%)
|
—
est: 156.77M (-100.0%)
|
134.20M
est: 148.55M (-9.7%)
|
166.80M
est: 95.51M (+74.6%)
|
—
est: 94.75M (-100.0%)
|
—
est: 29.72M (-100.0%)
|
12.00M
est: -44.51M (+127.0%)
|
-194.80M
est: -1.40B (+86.1%)
|
-212.50M
est: -1.40B (+84.8%)
|
-50.50M
est: -229.30M (+78.0%)
|
-137.40M
est: -171.51M (+19.9%)
|
-259.30M
est: -197.42M (-31.3%)
|
-120.70M
est: -206.44M (+41.5%)
|
-384.60M
est: -202.35M (-90.1%)
|
-212.80M
-213.17M – -212.42M
-5.2% YoY
|
-224.20M
-225.22M – -223.19M
-5.4% YoY
|
-237.28M
-238.32M – -236.24M
-5.8% YoY
|
-254.15M
-257.03M – -252.00M
-7.1% YoY
|
-254.85M
-257.74M – -252.69M
-0.3% YoY
|
| Net Income |
100.71M
est: 97.05M (+3.8%)
|
112.15M
est: 114.62M (-2.2%)
|
147.14M
est: 128.41M (+14.6%)
|
176.23M
est: 100.75M (+74.9%)
|
80.20M
est: 89.47M (-10.4%)
|
125.30M
est: 71.72M (+74.7%)
|
21.80M
est: 98.83M (-77.9%)
|
131.00M
est: 17.46M (+650.4%)
|
4.60M
est: -40.96M (+111.2%)
|
-223.70M
est: -1.18B (+81.0%)
|
-199.50M
est: -1.18B (+83.0%)
|
-27.20M
est: -47.96M (+43.3%)
|
-112.00M
est: -248.20M (+54.9%)
|
-263.30M
est: -166.37M (-58.3%)
|
-127.30M
est: 12.79M (-1,095.2%)
|
-365.90M
est: 912.6K (-40,194.3%)
|
3.21M
-12.85M – 19.28M
+252.2% YoY
|
18.07M
3.91M – 32.23M
+462.2% YoY
|
25.77M
25.44M – 26.10M
+42.7% YoY
|
47.27M
46.75M – 47.97M
+83.4% YoY
|
53.65M
53.06M – 54.44M
+13.5% YoY
|
| SGA |
169.84M
est: 167.02M (+1.7%)
|
208.38M
est: 210.27M (-0.9%)
|
251.84M
est: 201.78M (+24.8%)
|
327.10M
est: 332.56M (-1.6%)
|
366.00M
est: 341.44M (+7.2%)
|
359.10M
est: 410.59M (-12.5%)
|
476.40M
est: 373.69M (+27.5%)
|
467.10M
est: 420.86M (+11.0%)
|
556.60M
est: 673.20M (-17.3%)
|
500.70M
est: 494.29M (+1.3%)
|
507.30M
est: 494.29M (+2.6%)
|
537.80M
est: 534.39M (+0.6%)
|
514.70M
est: 668.45M (-23.0%)
|
572.90M
est: 580.58M (-1.3%)
|
560.00M
est: 607.12M (-7.8%)
|
537.60M
est: 595.07M (-9.7%)
|
625.80M
624.69M – 626.91M
+5.2% YoY
|
659.34M
656.35M – 662.33M
+5.4% YoY
|
697.80M
694.74M – 700.85M
+5.8% YoY
|
747.40M
741.08M – 755.88M
+7.1% YoY
|
749.46M
743.13M – 757.96M
+0.3% YoY
|
| EPS |
1.12
est: 1.03 (+8.7%)
|
1.33
est: 1.26 (+5.6%)
|
1.82
est: 1.22 (+49.8%)
|
2.33
est: 1.49 (+56.4%)
|
1.12
est: 1.46 (-23.1%)
|
1.79
est: 1.65 (+8.8%)
|
0.32
est: 1.02 (-68.6%)
|
1.89
est: 1.21 (+56.7%)
|
0.06
est: 1.71 (-96.3%)
|
-2.99
est: -0.19 (-1,473.7%)
|
-2.69
est: -0.19 (-1,313.2%)
|
-0.35
est: -0.73 (+51.7%)
|
-1.39
est: -0.34 (-304.9%)
|
-3.18
est: -1.78 (-78.7%)
|
-1.41
est: 0.13 (-1,167.9%)
|
-3.96
est: 0.01 (-40,661.3%)
|
0.07
-0.14 – 0.21
+605.6% YoY
|
0.16
0.04 – 0.35
+127.9% YoY
|
0.28
0.27 – 0.28
+75.6% YoY
|
0.51
0.50 – 0.51
+83.8% YoY
|
0.58
0.57 – 0.58
+13.5% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Wells Fargo | Equal Weight | Equal Weight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-12.46M
OE per share TTM
-0.13
Owner's Yield
-3.27%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
19.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
21.94M
Insider transactions (90d)
1
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 14.68M | 18.40% | 14.44M | — | 14.68M | — | HC | Delaware | 2022-01-27 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 9.15M | 11.46% | — | 64.1K | 9.02M | 132.0K | IA | Pennsylvania | 2022-02-10 | ↗ |
| 3 | Integrated Core Strategies (US) LLC | 4.54M | 5.00% | — | 4.54M | — | 4.54M | OO | Delaware | 2024-05-01 | ↗ |
| 4 | Israel A. Englander | 4.54M | 5.00% | — | 4.54M | — | 4.54M | IN | Delaware | 2024-05-01 | ↗ |
| 5 | Millennium Group Management LLC | 4.54M | 5.00% | — | 4.54M | — | 4.54M | OO | Delaware | 2024-05-01 | ↗ |
| 6 | Millennium Management LLC | 4.54M | 5.00% | — | 4.54M | — | 4.54M | OO | Delaware | 2024-05-01 | ↗ |
| 7 | STATE STREET CORPORATION | 4.41M | 5.52% | — | 4.26M | — | 4.41M | HC | — | 2022-02-11 | ↗ |
| 8 | Wellington Group Holdings LLP | 4.33M | 5.42% | — | 3.78M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 9 | Wellington Investment Advisors Holdings LLP | 4.33M | 5.42% | — | 3.78M | — | — | HC | Delaware | 2022-02-04 | ↗ |
| 10 | Wellington Management Group LLP | 4.33M | 5.42% | — | 3.78M | — | — | HC | Massachusetts | 2022-02-04 | ↗ |
| 11 | GLENVIEW CAPITAL MANAGEMENT, LLC | 4.31M | 5.31% | — | 4.31M | — | 4.31M | OO | United States of America | 2023-03-01 | ↗ |
| 12 | LARRY ROBBINS | 4.31M | 5.31% | — | 4.31M | — | 4.31M | HC, IN | United States of America | 2023-03-01 | ↗ |
| 13 | Wellington Management Company LLP | 4.19M | 5.25% | — | 3.74M | — | — | IA | Delaware | 2022-02-04 | ↗ |
| 14 | (. | 3.53M | 5.10% | 3.43M | — | 3.53M | — | IA | Delaware Limited Partnership | 2018-02-09 | ↗ |
| 15 | 13-3695715 | 3.22M | 4.30% | — | 3.12M | — | — | IA, PN | Delaware | 2021-02-16 | ↗ |
| 16 | David E. Shaw | 3.22M | 4.30% | — | 3.12M | — | — | IN | United States | 2021-02-16 | ↗ |
| 17 | Baillie Gifford & Co (Scottish partnership) | — | 11.00% | — | — | — | — | IA | SCOTLAND UK | 2020-07-07 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
44
-176 vs prev Q
New positions
7
Closed positions
182
Increased
19
Reduced
17
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 50.0K +50.0K (+100.0%) | 308.00M +308.0M (+100.0%) | 0.05% +0.054 pp | 0.00% +0.001 pp | USD6.15 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 15.30M +424.4K (+2.9%) | 94.12M -13.5M (-12.5%) | 16.44% +0.352 pp | 0.00% 0.000 pp | USD26.41 -76.7% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 8.23M +342.9K (+4.3%) | 50.59M -6.4M (-11.2%) | 8.84% +0.313 pp | 0.00% 0.000 pp | USD27.02 -77.2% | 84 qtrs — |
| 4 | MILLENNIUM MANAGEMENT LLC | 6.70M +2.0M (+41.1%) | 41.21M +6.9M (+20.0%) | 7.20% +2.063 pp | 0.02% +0.003 pp | USD13.75 -55.3% | 47 qtrs — |
| 5 | STATE STREET CORP | 5.97M +990.1K (+19.9%) | 36.69M +714.4K (+2.0%) | 6.41% +1.029 pp | 0.00% +0.000 pp | USD19.02 -67.7% | 51 qtrs — |
| 6 | GLENVIEW CAPITAL MANAGEMENT, LLC | 4.59M +— (+0.0%) | 28.21M -5.0M (-14.9%) | 4.93% -0.032 pp | 0.57% -0.164 pp | USD13.85 -55.6% | 26 qtrs — |
| 7 | D. E. SHAW & CO., INC. | 4.51M -53.9K (-1.2%) | 27.71M -5.3M (-15.9%) | 4.84% -0.090 pp | 0.02% -0.003 pp | USD11.67 -47.3% | 81 qtrs — |
| 8 | MORGAN STANLEY | 3.61M -9.1K (-0.3%) | 22.19M -4.0M (-15.2%) | 3.88% -0.035 pp | 0.00% 0.000 pp | USD9.33 -34.1% | 51 qtrs — |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.27M -172.5K (-7.1%) | 13.96M -3.7M (-20.9%) | 2.44% -0.202 pp | 0.05% -0.016 pp | USD6.48 -5.1% | 3 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.23M +6.1K (+0.3%) | 13.73M -2.4M (-14.7%) | 2.40% -0.009 pp | 0.00% 0.000 pp | USD24.61 -75.0% | 78 qtrs — |
| 11 | GOLDMAN SACHS GROUP INC | 2.16M +8.5K (+0.4%) | 13.29M -2.3M (-14.6%) | 2.32% -0.006 pp | 0.00% 0.000 pp | USD12.01 -48.8% | 73 qtrs — |
| 12 | AQR CAPITAL MANAGEMENT LLC | 1.87M +273.6K (+17.1%) | 11.50M -42.2K (-0.4%) | 2.01% +0.283 pp | 0.01% -0.001 pp | USD7.29 -15.6% | 68 qtrs — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.75M +74.8K (+4.5%) | 10.79M -1.4M (-11.1%) | 1.88% +0.069 pp | 0.00% 0.000 pp | USD19.80 -68.9% | 100 qtrs — |
| 14 | FEDERATED HERMES, INC. | 1.31M +181.1K (+16.0%) | 8.06M -106.4K (-1.3%) | 1.41% +0.187 pp | 0.01% -0.001 pp | USD5.45 +12.8% | 24 qtrs — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 1.29M -408.4K (-24.1%) | 7.92M -4.3M (-35.4%) | 1.38% -0.451 pp | 0.00% -0.001 pp | USD24.80 -75.2% | 51 qtrs — |
| 16 | POINT72 ASSET MANAGEMENT, L.P. | 1.23M +158.7K (+14.8%) | 7.58M -183.8K (-2.4%) | 1.32% +0.163 pp | 0.01% -0.005 pp | USD8.88 -30.7% | 33 qtrs — |
| 17 | VESTAL POINT CAPITAL, LP | 1.22M +623.0K (+103.8%) | 7.52M +3.2M (+73.4%) | 1.31% +0.665 pp | 0.26% +0.060 pp | USD6.68 -7.9% | 2 qtrs — |
| 18 | FISHER ASSET MANAGEMENT, LLC | 1.21M -71.9K (-5.6%) | 7.42M -1.8M (-19.7%) | 1.30% -0.086 pp | 0.00% -0.001 pp | USD16.22 -62.1% | 45 qtrs — |
| 19 | NUVEEN, LLC | 1.19M +465.7K (+64.2%) | 7.32M +2.1M (+39.7%) | 1.28% +0.495 pp | 0.00% +0.001 pp | USD7.81 -21.3% | 4 qtrs — |
| 20 | ASSENAGON ASSET MANAGEMENT S.A. | 1.17M -136.4K (-10.5%) | 7.18M -2.2M (-23.8%) | 1.25% -0.156 pp | 0.01% -0.003 pp | USD7.76 -20.7% | 19 qtrs — |
| 21 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 1.16M -120.0K (-9.4%) | 7.11M -2.1M (-22.9%) | 1.24% -0.138 pp | 0.02% -0.010 pp | USD10.67 -42.4% | 13 qtrs — |
| 22 | NORTHERN TRUST CORP | 1.13M -8.9K (-0.8%) | 6.93M -1.3M (-15.6%) | 1.21% -0.018 pp | 0.00% 0.000 pp | USD26.40 -76.7% | 51 qtrs — |
| 23 | ACADIAN ASSET MANAGEMENT LLC | 986.1K +175.6K (+21.7%) | 6.06M +203.0K (+3.5%) | 1.06% +0.183 pp | 0.01% 0.000 pp | USD5.46 +12.6% | 3 qtrs — |
| 24 | TWO SIGMA INVESTMENTS, LP | 915.2K +186.5K (+25.6%) | 5.63M +360.0K (+6.8%) | 0.98% +0.195 pp | 0.01% +0.000 pp | USD5.92 +3.9% | 4 qtrs — |
| 25 | ABRDN PLC | 885.8K +246.7K (+38.6%) | 5.45M +827.3K (+17.9%) | 0.95% +0.261 pp | 0.01% +0.001 pp | USD6.43 -4.4% | 3 qtrs — |
| 26 | QUBE RESEARCH & TECHNOLOGIES LTD | 873.1K -313.4K (-26.4%) | 5.37M -3.2M (-37.4%) | 0.94% -0.345 pp | 0.01% -0.003 pp | USD13.41 -54.1% | 11 qtrs — |
| 27 | BANK OF AMERICA CORP /DE/ | 867.1K +378.6K (+77.5%) | 5.33M +1.8M (+51.0%) | 0.93% +0.403 pp | 0.00% +0.000 pp | USD12.09 -49.1% | 52 qtrs — |
| 28 | WALLEYE CAPITAL LLC | 677.2K +277.3K (+69.4%) | 4.16M +1.3M (+44.1%) | 0.73% +0.295 pp | 0.01% +0.002 pp | USD6.90 -10.9% | 4 qtrs — |
| 29 | UBS GROUP AG | 639.7K +147.0K (+29.8%) | 3.93M +372.3K (+10.5%) | 0.69% +0.155 pp | 0.00% +0.000 pp | USD11.40 -46.1% | 45 qtrs — |
| 30 | ROYCE & ASSOCIATES LP | 605.0K -65.0K (-9.7%) | 3.72M -1.1M (-23.2%) | 0.65% -0.075 pp | 0.04% -0.011 pp | USD7.23 -14.9% | 2 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 582.1K -2.8K (-0.5%) | 3.58M -649.3K (-15.4%) | 0.63% -0.007 pp | 0.00% 0.000 pp | USD24.71 -75.1% | 66 qtrs — |
| 32 | TREXQUANT INVESTMENT LP | 542.5K +143.2K (+35.9%) | 3.34M +449.5K (+15.6%) | 0.58% +0.151 pp | 0.03% +0.000 pp | USD6.94 -11.4% | 7 qtrs — |
| 33 | AMERIPRISE FINANCIAL INC | 525.3K -17.8K (-3.3%) | 3.23M -695.7K (-17.7%) | 0.56% -0.023 pp | 0.00% 0.000 pp | USD13.72 -55.2% | 36 qtrs — |
| 34 | INVESCO LTD. | 507.2K +12.0K (+2.4%) | 3.12M -460.8K (-12.9%) | 0.54% +0.010 pp | 0.00% 0.000 pp | USD17.40 -64.7% | 57 qtrs — |
| 35 | FMR LLC | 490.9K +92.7K (+23.3%) | 3.02M +140.1K (+4.9%) | 0.53% +0.097 pp | 0.00% +0.000 pp | USD9.50 -35.3% | 70 qtrs — |
| 36 | HRT FINANCIAL LP | 468.9K -321.7K (-40.7%) | 2.88M -2.8M (-49.6%) | 0.50% -0.351 pp | 0.01% -0.012 pp | USD6.89 -10.7% | 3 qtrs — |
| 37 | PRINCIPAL FINANCIAL GROUP INC | 444.1K -5.0K (-1.1%) | 2.73M -515.7K (-15.9%) | 0.48% -0.009 pp | 0.00% 0.000 pp | USD21.08 -70.8% | 70 qtrs — |
| 38 | WELLS FARGO & COMPANY/MN | 437.0K -71.2K (-14.0%) | 2.69M -986.8K (-26.9%) | 0.47% -0.080 pp | 0.00% 0.000 pp | USD11.68 -47.3% | 57 qtrs — |
| 39 | CANADA PENSION PLAN INVESTMENT BOARD | 436.9K +128.8K (+41.8%) | 2.69M +459.4K (+20.6%) | 0.47% +0.136 pp | 0.00% +0.000 pp | USD5.56 +10.6% | 3 qtrs — |
| 40 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 383.7K +— (+0.0%) | 2.36M -414.3K (-14.9%) | 0.41% -0.003 pp | 0.04% -0.008 pp | USD5.31 +15.8% | 3 qtrs — |
| 41 | JPMORGAN CHASE & CO | 380.1K -172.2K (-31.2%) | 2.34M -1.7M (-41.5%) | 0.41% -0.189 pp | 0.00% 0.000 pp | USD18.10 -66.0% | 51 qtrs — |
| 42 | RENAISSANCE TECHNOLOGIES LLC | 379.4K +357.7K (+1,650.4%) | 2.33M +2.2M (+1,388.9%) | 0.41% +0.384 pp | 0.00% +0.003 pp | USD6.60 -6.8% | 6 qtrs — |
| 43 | NORDEA INVESTMENT MANAGEMENT AB | 369.2K -47.0K (-11.3%) | 2.26M -702.7K (-23.7%) | 0.40% -0.053 pp | 0.00% -0.001 pp | USD15.89 -61.3% | 39 qtrs — |
| 44 | ALGERT GLOBAL LLC | 365.5K -547.6K (-60.0%) | 2.25M -4.4M (-65.9%) | 0.39% -0.595 pp | 0.04% -0.075 pp | USD7.23 -14.9% | 7 qtrs — |
| 45 | Y-INTERCEPT (HONG KONG) LTD | 356.9K +171.8K (+92.8%) | 2.19M +856.9K (+64.0%) | 0.38% +0.183 pp | 0.05% +0.017 pp | USD9.09 -32.3% | 10 qtrs — |
| 46 | SQUAREPOINT OPS LLC | 343.7K +225.4K (+190.6%) | 2.11M +1.3M (+147.1%) | 0.37% +0.241 pp | 0.00% +0.001 pp | USD9.13 -32.6% | 14 qtrs — |
| 47 | TWO SIGMA ADVISERS, LP | 340.2K +6.8K (+2.0%) | 2.09M -318.3K (-13.2%) | 0.37% +0.005 pp | 0.00% -0.001 pp | USD5.58 +10.2% | 3 qtrs — |
| 48 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 322.4K -40.5K (-11.2%) | 1.98M -641.0K (-24.4%) | 0.35% -0.046 pp | 0.01% -0.003 pp | USD16.05 -61.7% | 36 qtrs — |
| 49 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 313.4K +291.8K (+1,354.8%) | 1.93M +1.8M (+1,137.5%) | 0.34% +0.313 pp | 0.02% +0.014 pp | USD6.34 -3.0% | 4 qtrs — |
| 50 | BNP PARIBAS ARBITRAGE, SNC | 305.0K -79.7K (-20.7%) | 1.88M -905.7K (-32.6%) | 0.33% -0.088 pp | 0.00% -0.001 pp | USD8.73 -29.6% | 49 qtrs — |
| 51 | BARCLAYS PLC | 301.8K +111.5K (+58.6%) | 1.86M -3.4M (-64.4%) | 0.32% +0.119 pp | 0.00% -0.001 pp | USD11.49 -46.5% | 51 qtrs — |
| 52 | STATE OF WISCONSIN INVESTMENT BOARD | 287.6K -11.2K (-3.8%) | 1.77M -391.7K (-18.1%) | 0.31% -0.014 pp | 0.00% -0.001 pp | USD10.52 -41.5% | 35 qtrs — |
| 53 | RHUMBLINE ADVISERS | 275.9K -14.2K (-4.9%) | 1.70M -400.5K (-19.1%) | 0.30% -0.017 pp | 0.00% 0.000 pp | USD21.79 -71.8% | 52 qtrs — |
| 54 | CITADEL ADVISORS LLC | 272.8K -299.4K (-52.3%) | 1.68M -2.5M (-59.4%) | 0.29% -0.326 pp | 0.00% 0.000 pp | USD8.10 -24.1% | 13 qtrs — |
| 55 | INTECH INVESTMENT MANAGEMENT LLC | 228.8K +193.2K (+543.3%) | 1.41M +1.1M (+447.2%) | 0.25% +0.207 pp | 0.01% +0.010 pp | USD7.82 -21.4% | 7 qtrs — |
| 56 | IEQ CAPITAL, LLC | 228.0K +66.5K (+41.1%) | 1.40M +234.3K (+20.1%) | 0.24% +0.070 pp | 0.00% +0.001 pp | USD6.55 -6.1% | 4 qtrs — |
| 57 | UBS ASSET MANAGEMENT AMERICAS INC | 224.1K +23.3K (+11.6%) | 1.38M -73.9K (-5.1%) | 0.24% +0.024 pp | 0.00% +0.000 pp | USD17.08 -64.0% | 55 qtrs — |
| 58 | LEGAL & GENERAL GROUP PLC | 220.5K -12.8K (-5.5%) | 1.36M -330.8K (-19.6%) | 0.24% -0.015 pp | 0.00% 0.000 pp | USD24.73 -75.1% | 44 qtrs — |
| 59 | JAIN GLOBAL LLC | 189.0K +111.5K (+143.9%) | 1.16M +602.0K (+107.5%) | 0.20% +0.119 pp | 0.01% +0.003 pp | USD6.26 -1.8% | 4 qtrs — |
| 60 | GSA CAPITAL PARTNERS LLP | 187.8K +187.8K (+100.0%) | 1.16M +1.2M (+100.0%) | 0.20% +0.202 pp | 0.10% +0.100 pp | USD6.15 +0.0% | 6 qtrs — |
| 61 | SWISS NATIONAL BANK | 183.4K +7.1K (+4.0%) | 1.13M -146.7K (-11.5%) | 0.20% +0.006 pp | 0.00% 0.000 pp | USD25.99 -76.3% | 51 qtrs — |
| 62 | JUMP FINANCIAL, LLC | 168.6K +7.0K (+4.3%) | 1.04M -131.6K (-11.3%) | 0.18% +0.006 pp | 0.01% -0.001 pp | USD7.29 -15.6% | 6 qtrs — |
| 63 | RUSSELL INVESTMENTS GROUP, LTD. | 167.1K -6.1K (-3.5%) | 1.03M -224.7K (-17.9%) | 0.18% -0.008 pp | 0.00% 0.000 pp | USD6.32 -2.7% | 3 qtrs — |
| 64 | RAFFERTY ASSET MANAGEMENT, LLC | 149.2K +36.4K (+32.3%) | 917.8K +102.3K (+12.5%) | 0.16% +0.038 pp | 0.00% +0.001 pp | USD16.51 -62.7% | 30 qtrs — |
| 65 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 137.4K +180.0 (+0.1%) | 845.3K -147.1K (-14.8%) | 0.15% -0.001 pp | 0.00% -0.001 pp | USD6.54 -6.0% | 51 qtrs — |
| 66 | MARTINGALE ASSET MANAGEMENT L P | 128.9K +54.9K (+74.1%) | 792.8K +257.6K (+48.1%) | 0.14% +0.058 pp | 0.02% +0.007 pp | USD6.77 -9.2% | 2 qtrs — |
| 67 | LOS ANGELES CAPITAL MANAGEMENT LLC | 97.4K +16.0K (+19.7%) | 774.5K +186.0K (+31.6%) | 0.10% +0.017 pp | 0.00% +0.001 pp | USD7.05 -12.8% | 2 qtrs — |
| 68 | DEUTSCHE BANK AG\ | 123.2K -276.3K (-69.2%) | 757.6K -2.1M (-73.8%) | 0.13% -0.300 pp | 0.00% -0.001 pp | USD9.09 -32.3% | 50 qtrs — |
| 69 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 117.4K +117.4K (+100.0%) | 722.2K +722.2K (+100.0%) | 0.13% +0.126 pp | 0.00% +0.000 pp | USD6.15 +0.0% | 1 qtrs NEW |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 107.0K +141.0 (+0.1%) | 658.1K -114.4K (-14.8%) | 0.11% -0.001 pp | 0.00% 0.000 pp | USD23.53 -73.9% | 7 qtrs — |
| 71 | PRUDENTIAL FINANCIAL INC | 105.2K -3.3K (-3.0%) | 647.0K -137.4K (-17.5%) | 0.11% -0.004 pp | 0.00% 0.000 pp | USD15.76 -61.0% | 43 qtrs — |
| 72 | VOYA INVESTMENT MANAGEMENT LLC | 104.1K +1.7K (+1.7%) | 640.4K -99.8K (-13.5%) | 0.11% +0.001 pp | 0.00% 0.000 pp | USD15.69 -60.8% | 51 qtrs — |
| 73 | FRANKLIN RESOURCES INC | 103.4K +2.7K (+2.7%) | 635.8K -92.0K (-12.6%) | 0.11% +0.002 pp | 0.00% +0.000 pp | USD15.12 -59.3% | 11 qtrs — |
| 74 | ALLIANCEBERNSTEIN L.P. | 99.5K -1.8K (-1.8%) | 611.6K -120.3K (-16.4%) | 0.11% -0.003 pp | 0.00% +0.000 pp | USD28.20 -78.2% | 61 qtrs — |
| 75 | SCHONFELD STRATEGIC ADVISORS LLC | 95.0K +39.6K (+71.4%) | 584.5K +183.6K (+45.8%) | 0.10% +0.042 pp | 0.00% +0.000 pp | USD10.49 -41.4% | 7 qtrs — |
| 76 | INSPIRE INVESTING, LLC | 90.3K +10.6K (+13.3%) | 555.2K -21.0K (-3.6%) | 0.10% +0.011 pp | 0.05% -0.006 pp | USD9.47 -35.1% | 22 qtrs — |
| 77 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 89.9K -13.7K (-13.3%) | 553.0K -196.5K (-26.2%) | 0.10% -0.016 pp | 0.00% 0.000 pp | USD23.42 -73.7% | 52 qtrs — |
| 78 | HEADLANDS TECHNOLOGIES LLC | 86.8K +10.4K (+13.6%) | 533.8K -18.5K (-3.4%) | 0.09% +0.011 pp | 0.04% +0.000 pp | USD8.91 -31.0% | 7 qtrs — |
| 79 | CERITY PARTNERS LLC | 86.5K +6.9K (+8.7%) | 531.8K -43.3K (-7.5%) | 0.09% +0.007 pp | 0.00% 0.000 pp | USD6.65 -7.5% | 3 qtrs — |
| 80 | AQUATIC CAPITAL MANAGEMENT LLC | 82.6K +31.7K (+62.3%) | 507.9K +140.0K (+38.1%) | 0.09% +0.034 pp | 0.01% +0.008 pp | USD9.29 -33.8% | 14 qtrs — |
| 81 | MAN GROUP PLC | 82.0K +82.0K (+100.0%) | 504.0K +504.0K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.001 pp | USD6.15 +0.0% | 5 qtrs — |
| 82 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 80.2K -6.4K (-7.4%) | 493.0K -132.0K (-21.1%) | 0.09% -0.007 pp | 0.00% +0.000 pp | USD23.48 -73.8% | 49 qtrs — |
| 83 | AMERICAN CENTURY COMPANIES INC | 77.5K +21.7K (+38.9%) | 476.5K +73.1K (+18.1%) | 0.08% +0.023 pp | 0.00% +0.000 pp | USD6.67 -7.8% | 20 qtrs — |
| 84 | THRIVENT FINANCIAL FOR LUTHERANS | 75.3K -3.1K (-3.9%) | 463.0K -103.0K (-18.2%) | 0.08% -0.004 pp | 0.00% 0.000 pp | USD22.26 -72.4% | 36 qtrs — |
| 85 | PRICE T ROWE ASSOCIATES INC /MD/ | 74.5K +14.3K (+23.7%) | 459.0K +23.0K (+5.3%) | 0.08% +0.015 pp | 0.00% +0.000 pp | USD16.96 -63.7% | 75 qtrs — |
| 86 | CREATIVE PLANNING | 73.7K -4.0K (-5.1%) | 453.5K -108.4K (-19.3%) | 0.08% -0.005 pp | 0.00% 0.000 pp | USD7.51 -18.1% | 7 qtrs — |
| 87 | CWM, LLC | 71.8K +8.4K (+13.3%) | 441.0K -17.0K (-3.7%) | 0.08% +0.009 pp | 0.00% 0.000 pp | USD7.27 -15.4% | 17 qtrs — |
| 88 | QUANTINNO CAPITAL MANAGEMENT LP | 71.4K +45.3K (+172.8%) | 439.4K +250.0K (+132.0%) | 0.08% +0.048 pp | 0.00% +0.000 pp | USD5.99 +2.7% | 3 qtrs — |
| 89 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 71.0K +— (+0.0%) | 437.0K -76.0K (-14.8%) | 0.08% -0.001 pp | 0.00% 0.000 pp | USD26.23 -76.6% | 40 qtrs — |
| 90 | VOLEON CAPITAL MANAGEMENT LP | 68.8K -45.7K (-39.9%) | 423.2K -404.9K (-48.9%) | 0.07% -0.050 pp | 0.01% -0.011 pp | USD6.08 +1.2% | 3 qtrs — |
| 91 | ENGINEERS GATE MANAGER LP | 64.5K -34.7K (-35.0%) | 396.9K -320.6K (-44.7%) | 0.07% -0.038 pp | 0.00% -0.004 pp | USD15.43 -60.1% | 11 qtrs — |
| 92 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 62.7K -94.3K (-60.1%) | 385.5K -749.2K (-66.0%) | 0.07% -0.102 pp | 0.00% 0.000 pp | USD9.34 -34.2% | 27 qtrs — |
| 93 | PROFUND ADVISORS LLC | 62.1K +34.8K (+127.8%) | 381.7K +184.7K (+93.7%) | 0.07% +0.037 pp | 0.01% +0.005 pp | USD12.39 -50.4% | 12 qtrs — |
| 94 | PHARVISION ADVISERS, LLC | 58.5K +58.5K (+100.0%) | 359.8K +359.8K (+100.0%) | 0.06% +0.063 pp | 0.18% +0.182 pp | USD6.15 +0.0% | 1 qtrs NEW |
| 95 | JANE STREET GROUP, LLC | 54.4K -169.6K (-75.7%) | 334.7K -1.3M (-79.3%) | 0.06% -0.184 pp | 0.00% 0.000 pp | USD7.23 -14.9% | 26 qtrs — |
| 96 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 51.3K -205.0 (-0.4%) | 314.0K -57.0K (-15.4%) | 0.06% -0.001 pp | 0.00% -0.001 pp | USD22.70 -72.9% | 36 qtrs — |
| 97 | MARINER, LLC | 48.2K +19.5K (+68.2%) | 296.3K +89.2K (+43.1%) | 0.05% +0.021 pp | 0.00% +0.000 pp | USD6.32 -2.7% | 3 qtrs — |
| 98 | TUDOR INVESTMENT CORP ET AL | 44.8K +44.8K (+100.0%) | 275.6K +275.6K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.001 pp | USD6.15 +0.0% | 6 qtrs — |
| 99 | METLIFE INVESTMENT MANAGEMENT, LLC | 42.9K -10.3K (-19.4%) | 264.1K -121.1K (-31.4%) | 0.05% -0.012 pp | 0.00% -0.001 pp | USD28.61 -78.5% | 33 qtrs — |
| 100 | LOUISIANA STATE EMPLOYEES RETIREMENT SYSTEM | 42.7K -100.0 (-0.2%) | 262.6K -46.8K (-15.1%) | 0.05% 0.000 pp | 0.00% -0.001 pp | USD19.67 -68.7% | 36 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
2.0K
Cash buys
—
Cash sales
—
Net activity
-2,015
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Donnelly Brian J | Officer | F-InKind | D | Common Stock | 55,975 | 4.80 | 268.7K | 568,363 | D | ↗ |
| 2026-04-14 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,069 | 4.91 | 5.2K | 629,646 | D | ↗ |
| 2026-04-14 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 946 | 4.91 | 4.6K | 326,310 | D | ↗ |
| 2026-03-22 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 549 | 4.58 | 2.5K | 298,509 | D | ↗ |
| 2026-03-22 | Verratti Mark | Officer | F-InKind | D | Common Stock | 2,055 | 4.58 | 9.4K | 630,715 | D | ↗ |
| 2026-03-22 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 2,019 | 4.58 | 9.2K | 327,256 | D | ↗ |
| 2026-03-15 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 2,192 | 4.66 | 10.2K | 299,058 | D | ↗ |
| 2026-03-15 | Verratti Mark | Officer | F-InKind | D | Common Stock | 5,611 | 4.66 | 26.1K | 641,866 | D | ↗ |
| 2026-03-15 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 11,949 | 4.66 | 55.7K | 329,275 | D | ↗ |
| 2026-03-15 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 3,355 | 4.66 | 15.6K | 188,404 | D | ↗ |
| 2026-03-14 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 1,097 | 4.66 | 5.1K | 302,127 | D | ↗ |
| 2026-03-14 | Verratti Mark | Officer | F-InKind | D | Common Stock | 5,418 | 4.66 | 25.2K | 647,477 | D | ↗ |
| 2026-03-14 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 5,784 | 4.66 | 27.0K | 267,801 | D | ↗ |
| 2026-03-14 | Raha Samraat S. | Director / Officer | F-InKind | D | Common Stock | 10,816 | 4.66 | 50.4K | 1,064,541 | D | ↗ |
| 2026-03-14 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 8,288 | 4.66 | 38.6K | 346,007 | D | ↗ |
| 2026-03-14 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 4,161 | 4.66 | 19.4K | 191,759 | D | ↗ |
| 2026-03-13 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 586 | 4.66 | 2.7K | 303,224 | D | ↗ |
| 2026-03-13 | Verratti Mark | Officer | F-InKind | D | Common Stock | 9,164 | 4.66 | 42.7K | 652,895 | D | ↗ |
| 2026-03-13 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 8,899 | 4.66 | 41.5K | 273,585 | D | ↗ |
| 2026-03-13 | Raha Samraat S. | Director / Officer | F-InKind | D | Common Stock | 36,304 | 4.66 | 169.2K | 1,075,357 | D | ↗ |
| 2026-03-13 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 12,779 | 4.66 | 59.6K | 354,295 | D | ↗ |
| 2026-03-13 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 6,412 | 4.66 | 29.9K | 195,920 | D | ↗ |
| 2026-03-13 | Fox Jennifer Lynne | Officer | F-InKind | D | Common Stock | 5,995 | 4.66 | 27.9K | 310,362 | D | ↗ |
| 2026-03-12 | Wheeler Benjamin Richard | Officer | A-Award | A | Common Stock | 206,186 | 0.00 | — | 303,810 | D | ↗ |
| 2026-03-12 | Verratti Mark | Officer | A-Award | A | Common Stock | 247,423 | 0.00 | — | 662,059 | D | ↗ |
| 2026-03-12 | Solaiman Shereen | Officer | A-Award | A | Common Stock | 173,196 | 0.00 | — | 282,484 | D | ↗ |
| 2026-03-12 | Raha Samraat S. | Director / Officer | A-Award | A | Common Stock | 618,557 | 0.00 | — | 1,111,661 | D | ↗ |
| 2026-03-12 | Muzzey Dale | Officer | A-Award | A | Common Stock | 173,196 | 0.00 | — | 367,074 | D | ↗ |
| 2026-03-12 | Fox Jennifer Lynne | Officer | A-Award | A | Common Stock | 195,876 | 0.00 | — | 316,357 | D | ↗ |
| 2026-03-12 | Donnelly Brian J | Officer | A-Award | A | Common Stock | 226,804 | 0.00 | — | 624,338 | D | ↗ |
| 2026-03-09 | Raha Samraat S. | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 5.00 | 199.8K | 493,104 | D | ↗ |
| 2026-03-01 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 1,675 | 4.61 | 7.7K | 109,288 | D | ↗ |
| 2026-02-27 | Phanstiel S. Louise | Director | P-Purchase | A | Common Stock | 48,000 | 4.66 | 223.7K | 281,951 | D | ↗ |
| 2026-02-26 | Phanstiel S. Louise | Director | P-Purchase | A | Common Stock | 50,407 | 4.80 | 242.1K | 233,951 | D | ↗ |
| 2026-02-25 | Phanstiel S. Louise | Director | P-Purchase | A | Common Stock | 6,100 | 4.74 | 28.9K | 183,544 | D | ↗ |
| 2026-02-02 | Wheeler Benjamin Richard | Officer | A-Award | A | Common Stock | 4,994 | 0.00 | — | 97,624 | D | ↗ |
| 2026-02-02 | Verratti Mark | Officer | A-Award | A | Common Stock | 32,810 | 0.00 | — | 414,636 | D | ↗ |
| 2026-02-02 | Muzzey Dale | Officer | A-Award | A | Common Stock | 23,697 | 0.00 | — | 193,878 | D | ↗ |
| 2026-02-02 | Haas Kevin Richard | Officer | A-Award | A | Common Stock | 23,697 | 0.00 | — | 202,332 | D | ↗ |
| 2026-01-01 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 418 | 6.15 | 2.6K | 170,181 | D | ↗ |
| 2025-12-25 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 21 | 6.55 | 137.55 | 92,630 | D | ↗ |
| 2025-12-11 | Raha Samraat S. | Director / Officer | F-InKind | D | Common Stock | 29,634 | 7.30 | 216.3K | 453,104 | D | ↗ |
| 2025-11-03 | Ancona Margaret | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-24 | Munk Natalie | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-21 | Wheeler Benjamin Richard | Officer | F-InKind | D | Common Stock | 2,559 | 7.77 | 19.9K | 92,651 | D | ↗ |
| 2025-09-21 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,085 | 7.77 | 8.4K | 381,826 | D | ↗ |
| 2025-09-21 | Munk Natalie | Officer | F-InKind | D | Common Stock | 962 | 7.77 | 7.5K | 45,167 | D | ↗ |
| 2025-09-21 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 958 | 7.77 | 7.4K | 127,726 | D | ↗ |
| 2025-09-03 | Fox Jennifer Lynne | Officer | F-InKind | D | Common Stock | 4,435 | 6.80 | 30.2K | 120,481 | D | ↗ |
| 2025-08-18 | Leffler Scott J. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-16 | Wheeler Benjamin Richard | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 95,210 | D | ↗ |
| 2025-06-05 | Skovronsky Daniel | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 135,806 | D | ↗ |
| 2025-06-05 | Reitan Colleen F | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 92,329 | D | ↗ |
| 2025-06-05 | Phanstiel S. Louise | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 177,444 | D | ↗ |
| 2025-06-05 | Newcomer Lee Nisley | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 132,141 | D | ↗ |
| 2025-06-05 | Kumar Rashmi | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 127,188 | D | ↗ |
| 2025-06-05 | Dreismann Heinrich | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 171,444 | D | ↗ |
| 2025-06-05 | Davis Mark Steven | Director | A-Award | A | Common Stock | 24,148 | 0.00 | — | 46,964 | D | ↗ |
| 2025-06-05 | Bisaro Paul | Director | A-Award | A | Common Stock | 49,796 | 0.00 | — | 89,941 | D | ↗ |
| 2025-05-31 | Raha Samraat S. | Director / Officer | A-Award | A | Common Stock | 1,498 | 3.56 | 5.3K | 482,738 | D | ↗ |
| 2025-05-01 | Donnelly Brian J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-30 | Verratti Mark | Officer | A-Award | A | Performance-Based Restricted Stock Units | 105,785 | 0.00 | — | 105,785 | D | ↗ |
| 2025-04-30 | Raha Samraat S. | Director / Officer | A-Award | A | Performance-Based Restricted Stock Units | 141,050 | 0.00 | — | 141,050 | D | ↗ |
| 2025-04-30 | DIAZ PAUL J | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-14 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,085 | 8.08 | 8.8K | 382,911 | D | ↗ |
| 2025-04-14 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 942 | 8.08 | 7.6K | 170,599 | D | ↗ |
| 2025-03-25 | Munk Natalie | Officer | F-InKind | D | Common Stock | 362 | 9.73 | 3.5K | 46,129 | D | ↗ |
| 2025-03-24 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,605 | 9.98 | 16.0K | 383,996 | D | ↗ |
| 2025-03-24 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 545 | 9.98 | 5.4K | 172,341 | D | ↗ |
| 2025-03-24 | Munk Natalie | Officer | F-InKind | D | Common Stock | 589 | 9.98 | 5.9K | 46,491 | D | ↗ |
| 2025-03-24 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 1,177 | 9.98 | 11.7K | 180,359 | D | ↗ |
| 2025-03-24 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 18,312 | 9.98 | 182.8K | 918,671 | D | ↗ |
| 2025-03-22 | Verratti Mark | Officer | F-InKind | D | Common Stock | 3,623 | 10.01 | 36.3K | 386,697 | D | ↗ |
| 2025-03-22 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 5,334 | 10.01 | 53.4K | 172,886 | D | ↗ |
| 2025-03-22 | Munk Natalie | Officer | F-InKind | D | Common Stock | 428 | 10.01 | 4.3K | 48,608 | D | ↗ |
| 2025-03-22 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 4,493 | 10.01 | 45.0K | 181,536 | D | ↗ |
| 2025-03-22 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 52,682 | 10.01 | 527.3K | 936,983 | D | ↗ |
| 2025-03-22 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 718 | 10.01 | 7.2K | 130,588 | D | ↗ |
| 2025-03-15 | Verratti Mark | Officer | F-InKind | D | Common Stock | 3,729 | 10.07 | 37.6K | 391,686 | D | ↗ |
| 2025-03-15 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 4,764 | 10.07 | 48.0K | 180,231 | D | ↗ |
| 2025-03-15 | Munk Natalie | Officer | F-InKind | D | Common Stock | 684 | 10.07 | 6.9K | 49,036 | D | ↗ |
| 2025-03-15 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 3,335 | 10.07 | 33.6K | 187,723 | D | ↗ |
| 2025-03-15 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 30,118 | 10.07 | 303.3K | 1,009,524 | D | ↗ |
| 2025-03-15 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 1,572 | 10.07 | 15.8K | 131,306 | D | ↗ |
| 2025-03-14 | Verratti Mark | Officer | F-InKind | D | Common Stock | 5,847 | 10.07 | 58.9K | 395,415 | D | ↗ |
| 2025-03-14 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 6,060 | 10.07 | 61.0K | 110,963 | D | ↗ |
| 2025-03-14 | Raha Samraat S. | Officer | F-InKind | D | Common Stock | 7,649 | 10.07 | 77.0K | 481,240 | D | ↗ |
| 2025-03-14 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 8,544 | 10.07 | 86.0K | 184,995 | D | ↗ |
| 2025-03-14 | Munk Natalie | Officer | F-InKind | D | Common Stock | 855 | 10.07 | 8.6K | 49,720 | D | ↗ |
| 2025-03-14 | Leffler Scott J. | Officer | F-InKind | D | Common Stock | 6,217 | 10.07 | 62.6K | 218,393 | D | ↗ |
| 2025-03-14 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 4,390 | 10.07 | 44.2K | 191,058 | D | ↗ |
| 2025-03-14 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 37,564 | 10.07 | 378.3K | 1,039,642 | D | ↗ |
| 2025-03-14 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 3,417 | 10.07 | 34.4K | 132,878 | D | ↗ |
| 2025-03-13 | Verratti Mark | Officer | A-Award | A | Common Stock | 99,227 | 0.00 | — | 401,262 | D | ↗ |
| 2025-03-13 | Solaiman Shereen | Officer | A-Award | A | Common Stock | 63,145 | 0.00 | — | 117,023 | D | ↗ |
| 2025-03-13 | Raha Samraat S. | Officer | A-Award | A | Common Stock | 216,495 | 0.00 | — | 488,889 | D | ↗ |
| 2025-03-13 | Muzzey Dale | Officer | A-Award | A | Common Stock | 75,773 | 0.00 | — | 193,539 | D | ↗ |
| 2025-03-13 | Munk Natalie | Officer | A-Award | A | Common Stock | 4,000 | 0.00 | — | 50,575 | D | ↗ |
| 2025-03-13 | Leffler Scott J. | Officer | A-Award | A | Common Stock | 72,165 | 0.00 | — | 224,610 | D | ↗ |
| 2025-03-13 | Haas Kevin Richard | Officer | A-Award | A | Common Stock | 54,124 | 0.00 | — | 195,448 | D | ↗ |
| 2025-03-13 | Fox Jennifer Lynne | Officer | A-Award | A | Common Stock | 63,145 | 0.00 | — | 124,916 | D | ↗ |
| 2025-03-13 | Ancona Margaret | Officer | A-Award | A | Common Stock | 54,124 | 0.00 | — | 136,295 | D | ↗ |
| 2025-03-01 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 1,912 | 10.73 | 20.5K | 53,878 | D | ↗ |
| 2025-02-25 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 1,016 | 11.74 | 11.9K | 128,566 | D | ↗ |
| 2025-02-25 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 2,697 | 11.74 | 31.7K | 75,703 | D | ↗ |
| 2025-02-07 | Verratti Mark | Officer | A-Award | A | Common Stock | 12,758 | 0.00 | — | 302,035 | D | ↗ |
| 2025-02-07 | Muzzey Dale | Officer | A-Award | A | Common Stock | 10,622 | 0.00 | — | 117,766 | D | ↗ |
| 2025-02-07 | Munk Natalie | Officer | A-Award | A | Common Stock | 3,316 | 0.00 | — | 46,575 | D | ↗ |
| 2025-02-07 | Haas Kevin Richard | Officer | A-Award | A | Common Stock | 12,758 | 0.00 | — | 141,324 | D | ↗ |
| 2025-02-07 | DIAZ PAUL J | Director / Officer | A-Award | A | Common Stock | 114,828 | 0.00 | — | 1,077,206 | D | ↗ |
| 2025-02-07 | Ancona Margaret | Officer | A-Award | A | Common Stock | 6,468 | 0.00 | — | 82,171 | D | ↗ |
| 2025-01-29 | Leffler Scott J. | Officer | F-InKind | D | Common Stock | 12,230 | 12.54 | 153.4K | 152,445 | D | ↗ |
| 2025-01-01 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 417 | 13.71 | 5.7K | 107,144 | D | ↗ |
| 2024-12-11 | Raha Samraat S. | Officer | F-InKind | D | Common Stock | 29,578 | 14.51 | 429.2K | 272,394 | D | ↗ |
| 2024-12-10 | Davis Mark Steven | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-11-30 | Raha Samraat S. | Officer | A-Award | A | Common Stock | 1,118 | 13.83 | 15.5K | 301,972 | D | ↗ |
| 2024-10-11 | DIAZ PAUL J | Director / Officer | S-Sale | D | Common Stock | 15,000 | 22.93 | 344.0K | 962,378 | D | ↗ |
| 2024-10-09 | Verratti Mark | Officer | F-InKind | D | Common Stock | 3,359 | 24.37 | 81.9K | 294,281 | D | ↗ |
| 2024-10-09 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 452 | 24.37 | 11.0K | 107,561 | D | ↗ |
| 2024-10-09 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 2,515 | 24.37 | 61.3K | 129,582 | D | ↗ |
| 2024-09-21 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,075 | 27.64 | 29.7K | 297,640 | D | ↗ |
| 2024-09-21 | Munk Natalie | Officer | F-InKind | D | Common Stock | 964 | 27.64 | 26.6K | 43,259 | D | ↗ |
| 2024-09-21 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 966 | 27.64 | 26.7K | 78,400 | D | ↗ |
| 2024-09-11 | Muzzey Dale | Officer | S-Sale | D | Common Stock | 2,100 | 26.17 | 55.0K | 108,013 | — | ↗ |
| 2024-09-11 | DIAZ PAUL J | Director / Officer | S-Sale | D | Common Stock | 15,000 | 26.72 | 400.8K | 977,378 | — | ↗ |
| 2024-09-09 | Dreismann Heinrich | Director | S-Sale | D | Common Stock | 10,000 | 27.05 | 270.5K | 121,648 | — | ↗ |
| 2024-09-03 | Reitan Colleen F | Director | S-Sale | D | Common Stock | 46,012 | 27.95 | 1.29M | 42,533 | — | ↗ |
| 2024-09-03 | Fox Jennifer Lynne | Officer | A-Award | A | Common Stock | 61,771 | 0.00 | — | 61,771 | — | ↗ |
| 2024-08-25 | Munk Natalie | Officer | F-InKind | D | Common Stock | 217 | 28.12 | 6.1K | 44,223 | — | ↗ |
| 2024-08-21 | Ancona Margaret | Officer | S-Sale | D | Common Stock | 11,538 | 27.82 | 321.0K | 79,366 | — | ↗ |
| 2024-08-19 | Kumar Rashmi | Director | S-Sale | D | Common Stock | 7,500 | 28.01 | 210.1K | 77,392 | — | ↗ |
| 2024-08-13 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 22,808 | 28.18 | 642.7K | 1,043,358 | — | ↗ |
| 2024-06-06 | Skovronsky Daniel | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 86,010 | — | ↗ |
| 2024-06-06 | SPIEGELMAN DANIEL K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-06 | Reitan Colleen F | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 88,545 | — | ↗ |
| 2024-06-06 | Phanstiel S. Louise | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 127,648 | — | ↗ |
| 2024-06-06 | Newcomer Lee Nisley | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 82,345 | — | ↗ |
| 2024-06-06 | Kumar Rashmi | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 84,892 | — | ↗ |
| 2024-06-06 | Dreismann Heinrich | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 131,648 | — | ↗ |
| 2024-06-06 | BISARO PAUL | Director | A-Award | A | Common Stock | 15,695 | 0.00 | — | 40,145 | — | ↗ |
| 2024-06-04 | SPIEGELMAN DANIEL K | Director | S-Sale | D | Common Stock | 3,788 | 22.05 | 83.5K | 32,917 | — | ↗ |
| 2024-06-03 | SPIEGELMAN DANIEL K | Director | S-Sale | D | Common Stock | 3,788 | 22.04 | 83.5K | 36,705 | — | ↗ |
| 2024-05-15 | DIAZ PAUL J | Director / Officer | S-Sale | D | Common Stock | 75,000 | 25.07 | 1.88M | 1,066,166 | — | ↗ |
| 2024-05-14 | DIAZ PAUL J | Director / Officer | S-Sale | D | Common Stock | 95,000 | 25.21 | 2.39M | 1,141,166 | — | ↗ |
| 2024-05-13 | Newcomer Lee Nisley | Director | S-Sale | D | Common Stock | 6,200 | 25.30 | 156.9K | 66,650 | — | ↗ |
| 2024-05-13 | DIAZ PAUL J | Director / Officer | S-Sale | D | Common Stock | 57,844 | 25.13 | 1.45M | 1,236,166 | — | ↗ |
| 2024-04-14 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,076 | 19.55 | 21.0K | 298,715 | — | ↗ |
| 2024-04-14 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 940 | 19.55 | 18.4K | 110,113 | — | ↗ |
| 2024-04-06 | Munk Natalie | Officer | F-InKind | D | Common Stock | 581 | 20.26 | 11.8K | 44,440 | — | ↗ |
| 2024-03-25 | Munk Natalie | Officer | F-InKind | D | Common Stock | 363 | 21.98 | 8.0K | 45,021 | — | ↗ |
| 2024-03-24 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,661 | 22.24 | 36.9K | 301,375 | — | ↗ |
| 2024-03-24 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 561 | 22.24 | 12.5K | 111,053 | — | ↗ |
| 2024-03-24 | Munk Natalie | Officer | F-InKind | D | Common Stock | 580 | 22.24 | 12.9K | 45,384 | — | ↗ |
| 2024-03-24 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 1,718 | 22.24 | 38.2K | 132,097 | — | ↗ |
| 2024-03-24 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 18,589 | 22.24 | 413.4K | 1,321,243 | — | ↗ |
| 2024-03-22 | Wong Pamela | Officer | F-InKind | D | Common Stock | 1,441 | 22.24 | 32.0K | 65,002 | — | ↗ |
| 2024-03-22 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,648 | 22.24 | 36.7K | 303,036 | — | ↗ |
| 2024-03-22 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 1,405 | 22.24 | 31.2K | 111,996 | — | ↗ |
| 2024-03-22 | Munk Natalie | Officer | F-InKind | D | Common Stock | 363 | 22.24 | 8.1K | 46,365 | — | ↗ |
| 2024-03-22 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 1,685 | 22.24 | 37.5K | 134,987 | — | ↗ |
| 2024-03-22 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 20,202 | 22.24 | 449.3K | 1,339,832 | — | ↗ |
| 2024-03-22 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 730 | 22.24 | 16.2K | 90,904 | — | ↗ |
| 2024-03-15 | Wong Pamela | Officer | F-InKind | D | Common Stock | 2,568 | 21.16 | 54.3K | 66,443 | — | ↗ |
| 2024-03-15 | Verratti Mark | Officer | F-InKind | D | Common Stock | 3,686 | 21.16 | 78.0K | 304,684 | — | ↗ |
| 2024-03-15 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 3,322 | 21.16 | 70.3K | 113,401 | — | ↗ |
| 2024-03-15 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 3,306 | 21.16 | 70.0K | 136,672 | — | ↗ |
| 2024-03-15 | DIAZ PAUL J | Director / Officer | F-InKind | D | Common Stock | 30,610 | 21.16 | 647.7K | 1,360,034 | — | ↗ |
| 2024-03-15 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 1,585 | 21.16 | 33.5K | 91,634 | — | ↗ |
| 2024-03-14 | Verratti Mark | Officer | A-Award | A | Common Stock | 58,631 | 0.00 | — | 308,370 | — | ↗ |
| 2024-03-14 | Solaiman Shereen | Officer | A-Award | A | Common Stock | 41,042 | 0.00 | — | 55,790 | — | ↗ |
| 2024-03-14 | Raha Samraat S. | Officer | A-Award | A | Common Stock | 64,494 | 0.00 | — | 300,854 | — | ↗ |
| 2024-03-14 | Muzzey Dale | Officer | A-Award | A | Common Stock | 49,250 | 0.00 | — | 116,723 | — | ↗ |
| 2024-03-14 | Munk Natalie | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 46,728 | — | ↗ |
| 2024-03-14 | Leffler Scott J. | Officer | A-Award | A | Common Stock | 46,095 | 0.00 | — | 163,865 | — | ↗ |
| 2024-03-14 | Haas Kevin Richard | Officer | A-Award | A | Common Stock | 35,178 | 0.00 | — | 139,978 | — | ↗ |
| 2024-03-14 | DIAZ PAUL J | Director / Officer | A-Award | A | Common Stock | 246,248 | 0.00 | — | 1,390,644 | — | ↗ |
| 2024-03-14 | Ancona Margaret | Officer | A-Award | A | Common Stock | 35,178 | 0.00 | — | 93,219 | — | ↗ |
| 2024-03-01 | Solaiman Shereen | Officer | F-InKind | D | Common Stock | 1,108 | 22.18 | 24.6K | 14,748 | — | ↗ |
| 2024-02-25 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 881 | 22.72 | 20.0K | 104,800 | — | ↗ |
| 2024-02-25 | Ancona Margaret | Officer | F-InKind | D | Common Stock | 2,231 | 22.72 | 50.7K | 58,041 | — | ↗ |
| 2024-01-29 | Riggsbee Richard Bryan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-29 | Leffler Scott J. | Officer | A-Award | A | Common Stock | 117,770 | 0.00 | — | 117,770 | — | ↗ |
| 2024-01-01 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 303 | 19.14 | 5.8K | 67,473 | — | ↗ |
| 2023-12-11 | Raha Samraat S. | Officer | A-Award | A | Common Stock | 236,360 | 0.00 | — | 236,360 | — | ↗ |
| 2023-12-01 | Riggsbee Richard Bryan | Officer | S-Sale | D | Common Stock | 30,000 | 19.09 | 572.8K | 291,812 | — | ↗ |
| 2023-11-01 | Riggsbee Richard Bryan | Officer | S-Sale | D | Common Stock | 30,000 | 15.69 | 470.6K | 321,812 | — | ↗ |
| 2023-10-31 | Lambert Nicole | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-18 | Wong Pamela | Officer | F-InKind | D | Common Stock | 1,342 | 15.06 | 20.2K | 70,978 | — | ↗ |
| 2023-10-09 | Verratti Mark | Officer | F-InKind | D | Common Stock | 5,006 | 15.01 | 75.1K | 249,739 | — | ↗ |
| 2023-10-09 | Riggsbee Richard Bryan | Officer | F-InKind | D | Common Stock | 4,954 | 15.01 | 74.4K | 359,194 | — | ↗ |
| 2023-10-09 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 308 | 15.01 | 4.6K | 67,776 | — | ↗ |
| 2023-10-09 | Lambert Nicole | Officer | F-InKind | D | Common Stock | 7,247 | 15.01 | 108.8K | 223,993 | — | ↗ |
| 2023-10-09 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 1,710 | 15.01 | 25.7K | 105,681 | — | ↗ |
| 2023-09-26 | Verratti Mark | Officer | F-InKind | D | Common Stock | 3,523 | 15.99 | 56.3K | 258,105 | — | ↗ |
| 2023-09-26 | Riggsbee Richard Bryan | Officer | F-InKind | D | Common Stock | 4,517 | 15.99 | 72.2K | 364,148 | — | ↗ |
| 2023-09-26 | Muzzey Dale | Officer | F-InKind | D | Common Stock | 133 | 15.99 | 2.1K | 68,084 | — | ↗ |
| 2023-09-26 | Lambert Nicole | Officer | F-InKind | D | Common Stock | 4,402 | 15.99 | 70.4K | 236,104 | — | ↗ |
| 2023-09-26 | Haas Kevin Richard | Officer | F-InKind | D | Common Stock | 858 | 15.99 | 13.7K | 107,391 | — | ↗ |
| 2023-09-21 | Verratti Mark | Officer | F-InKind | D | Common Stock | 1,076 | 16.77 | 18.0K | 261,628 | — | ↗ |
| 2023-09-21 | Munk Natalie | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 39,228 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-140.6K
Shares Outstanding
93.51M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Brian J. Donnelly Chief Commercial Officer | 350.0K | 450.0K | 4.80M | — | 371.9K | 26.3K | 6.00M | 80.03% | ↗ |
| 2 | 2025 | Samraat S. Raha President and Chief Executive Officer | 856.9K | — | 3.99M | — | 814.7K | 25.5K | 5.69M | 70.16% | ↗ |
| 3 | 2025 | Mark S. Verratti Chief Operating Officer | 622.9K | — | 2.06M | — | 438.3K | 26.0K | 3.15M | 65.43% | ↗ |
| 4 | 2025 | Scott J. Leffler Former Chief Financial Officer | 393.8K | — | 1.07M | — | — | 1.28M | 2.74M | 39.02% | ↗ |
| 5 | 2025 | Margaret Ancona Former EVP, Strategy and Transformation | 330.9K | — | 800.8K | — | — | 763.6K | 1.90M | 42.25% | ↗ |
| 6 | 2025 | Dale Muzzey, Ph.D. Chief Scientific Officer | 506.4K | — | 1.12M | — | 221.7K | 13.8K | 1.86M | 60.18% | ↗ |
| 7 | 2025 | Benjamin R. Wheeler Chief Financial Officer | 408.5K | — | 759.2K | — | 325.4K | 14.8K | 1.51M | 50.35% | ↗ |
| 8 | 2025 | Paul J. Diaz Former President and Chief Executive Officer | 418.1K | — | — | — | — | 270.5K | 688.6K | 0.00% | ↗ |
| 9 | 2024 | Paul J. Diaz President and Chief Executive Officer | 1.12M | — | 11.11M | — | 1.36M | 39.5K | 13.63M | 81.53% | ↗ |
| 10 | 2024 | Paul J. Diaz Former President and Chief Executive Officer | 1.12M | — | 11.11M | — | 1.36M | 39.5K | 13.63M | 81.53% | ↗ |
| 11 | 2024 | Scott J. Leffler Former Chief Financial Officer | 487.6K | 400.0K | 4.79M | — | 428.5K | 44.5K | 6.15M | 77.89% | ↗ |
| 12 | 2024 | Scott J. Leffler Chief Financial Officer | 487.6K | 400.0K | 4.79M | — | 428.5K | 44.5K | 6.15M | 77.89% | ↗ |
| 13 | 2024 | Samraat S. Raha Chief Operating Officer | 750.0K | — | 2.91M | — | 706.5K | 22.1K | 4.39M | 66.31% | ↗ |
| 14 | 2024 | Samraat S. Raha President and Chief Executive Officer | 750.0K | — | 2.91M | — | 706.5K | 22.1K | 4.39M | 66.31% | ↗ |
| 15 | 2024 | Mark S. Verratti Chief Operating Officer | 552.3K | — | 2.65M | — | 489.7K | 24.1K | 3.71M | 71.28% | ↗ |
| 16 | 2024 | Mark S. Verratti Chief Commercial Officer | 552.3K | — | 2.65M | — | 489.7K | 24.1K | 3.71M | 71.28% | ↗ |
| 17 | 2024 | Dale Muzzey, Ph.D. Chief Scientific Officer | 499.4K | — | 2.22M | — | 265.1K | 18.7K | 3.01M | 73.95% | ↗ |
| 18 | 2024 | R. Bryan Riggsbee Former Chief Financial Officer | 70.6K | — | — | — | — | 49.3K | 119.9K | 0.00% | ↗ |
| 19 | 2023 | Paul J. Diaz Former President and Chief Executive Officer | 1.09M | — | 9.80M | — | 1.17M | 56.7K | 12.11M | 80.91% | ↗ |
| 20 | 2023 | Paul J. Diaz President and Chief Executive Officer | 1.09M | — | 9.80M | — | 1.17M | 56.7K | 12.11M | 80.91% | ↗ |
| 21 | 2023 | R. Bryan Riggsbee Former Chief Financial Officer | 562.3K | — | 4.81M | — | 431.8K | 29.7K | 5.84M | 82.46% | ↗ |
| 22 | 2023 | Samraat S. Raha Chief Operating Officer | 14.4K | 500.0K | 4.50M | — | — | 390.00 | 5.02M | 89.74% | ↗ |
| 23 | 2023 | Samraat S. Raha President and Chief Executive Officer | 14.4K | 500.0K | 4.50M | — | — | 390.00 | 5.02M | 89.74% | ↗ |
| 24 | 2023 | Nicole Lambert Former Chief Operating Officer | 448.7K | — | 3.81M | — | 394.0K | 65.6K | 4.72M | 80.75% | ↗ |
| 25 | 2023 | Mark S. Verratti Chief Operating Officer | 495.8K | — | 1.96M | — | 400.2K | 19.8K | 2.88M | 68.15% | ↗ |
| 26 | 2023 | Mark S. Verratti Chief Commercial Officer | 495.8K | — | 1.96M | — | 400.2K | 19.8K | 2.88M | 68.15% | ↗ |
| 27 | 2023 | Dale Muzzey, Ph.D. Chief Scientific Officer | 443.8K | 111.0K | 1.42M | — | 250.7K | 11.1K | 2.23M | 63.41% | ↗ |
| 28 | 2022 | Paul J. Diaz President and Chief Executive Officer | 1.04M | — | 9.51M | — | 766.5K | 67.3K | 11.39M | 83.52% | ↗ |
| 29 | 2022 | Jerry S. Lanchbury, Ph.D. Former Chief Scientific Officer | 49.3K | — | 3.22M | — | — | 859.7K | 4.13M | 77.99% | ↗ |
| 30 | 2022 | R. Bryan Riggsbee Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer | 544.9K | — | 2.03M | — | 274.5K | 25.7K | 2.87M | 70.56% | ↗ |
| 31 | 2022 | R. Bryan Riggsbee Former Chief Financial Officer | 544.9K | — | 2.03M | — | 274.5K | 25.7K | 2.87M | 70.56% | ↗ |
| 32 | 2022 | Nicole Lambert Chief Operating Officer | 498.9K | — | 1.85M | — | 213.0K | 35.0K | 2.60M | 71.24% | ↗ |
| 33 | 2022 | Nicole Lambert Former Chief Operating Officer | 498.9K | — | 1.85M | — | 213.0K | 35.0K | 2.60M | 71.24% | ↗ |
| 34 | 2022 | Mark S. Verratti Chief Commercial Officer | 464.4K | — | 1.30M | — | 313.3K | 17.2K | 2.09M | 62.00% | ↗ |
| 35 | 2022 | Kevin R. Haas, Ph.D. Chief Technology Officer | 396.7K | — | 1.06M | — | 163.0K | 20.7K | 1.64M | 64.56% | ↗ |
| 36 | 2021 | Paul J. Diaz President and Chief Executive Officer | 1.00M | 500.0K | 9.87M | — | 1.28M | 138.7K | 12.79M | 77.18% | ↗ |
| 37 | 2021 | R. Bryan Riggsbee Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer | 526.5K | — | 2.02M | — | 394.2K | 13.8K | 2.96M | 68.40% | ↗ |
| 38 | 2021 | R. Bryan Riggsbee Former Chief Financial Officer | 526.5K | — | 2.02M | — | 394.2K | 13.8K | 2.96M | 68.40% | ↗ |
| 39 | 2021 | Nicole Lambert Chief Operating Officer | 475.3K | — | 2.09M | — | 336.2K | 13.8K | 2.91M | 71.66% | ↗ |
| 40 | 2021 | Nicole Lambert Former Chief Operating Officer | 475.3K | — | 2.09M | — | 336.2K | 13.8K | 2.91M | 71.66% | ↗ |
| 41 | 2021 | Jerry S. Lanchbury, Ph.D. Former Chief Scientific Officer | 544.8K | — | 1.19M | — | 294.2K | 13.8K | 2.05M | 58.34% | ↗ |
| 42 | 2021 | Mark S. Verratti Chief Commercial Officer | 434.5K | — | 1.29M | — | 275.0K | 13.8K | 2.02M | 64.13% | ↗ |
| 43 | 2021 | Mark Verratti Chief Commercial Officer | 434.5K | — | 1.29M | — | 275.0K | 13.8K | 2.02M | 64.13% | ↗ |
| 44 | 2020 | R. Bryan Riggsbee Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer | 552.8K | — | 3.46M | — | 180.2K | 8.8K | 4.20M | 82.35% | ↗ |
| 45 | 2020 | Jerry S. Lanchbury, Ph.D. Former Chief Scientific Officer | 493.5K | — | 1.20M | — | 131.6K | 6.9K | 1.83M | 65.45% | ↗ |
| 46 | 2020 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 493.5K | — | 1.20M | — | 131.6K | 6.9K | 1.83M | 65.45% | ↗ |
| 47 | 2020 | Nicole Lambert Chief Operating Officer | 386.9K | — | 1.20M | — | 99.9K | 20.7K | 1.70M | 70.23% | ↗ |
| 48 | 2020 | Nicole Lambert Group President of Myriad Women’s Health, Oncology, and International | 386.9K | — | 1.20M | — | 99.9K | 20.7K | 1.70M | 70.23% | ↗ |
| 49 | 2019 | Mark C. Capone President and Chief Executive Officer and Director | 887.0K | 200.00 | 7.18M | — | 802.7K | 29.2K | 8.90M | 80.68% | ↗ |
| 50 | 2019 | Alexander Ford President, Myriad Genetic Laboratories | 519.2K | 200.00 | 2.39M | — | 293.2K | 26.6K | 3.23M | 74.03% | ↗ |
| 51 | 2019 | R. Bryan Riggsbee Chief Financial Officer and Treasurer | 466.7K | 200.00 | 2.39M | — | 260.7K | 19.0K | 3.14M | 76.22% | ↗ |
| 52 | 2019 | R. Bryan Riggsbee Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer | 466.7K | — | 2.39M | — | 260.7K | 19.2K | 3.14M | 76.22% | ↗ |
| 53 | 2019 | Jerry S. Lanchbury, Ph.D. Former Chief Scientific Officer | 508.6K | — | 1.91M | — | 250.2K | 12.9K | 2.69M | 71.27% | ↗ |
| 54 | 2019 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 508.6K | — | 1.91M | — | 250.2K | 12.9K | 2.69M | 71.27% | ↗ |
| 55 | 2019 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 508.6K | 200.00 | 1.91M | — | 250.2K | 12.7K | 2.69M | 71.27% | ↗ |
| 56 | 2019 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 508.6K | 200.00 | 1.91M | — | 231.9K | 12.7K | 2.67M | 71.76% | ↗ |
| 57 | 2018 | Mark C. Capone President and Chief Executive Officer* | 852.0K | — | 5.37M | — | 817.9K | 11.0K | 7.05M | 76.17% | ↗ |
| 58 | 2018 | Mark C. Capone President and Chief Executive Officer and Director | 852.0K | — | 5.37M | — | 817.9K | 11.0K | 7.05M | 76.17% | ↗ |
| 59 | 2018 | Alexander Ford President, Myriad Womens Health, Inc. | 499.2K | — | 1.95M | — | 296.5K | 11.0K | 2.76M | 70.78% | ↗ |
| 60 | 2018 | Alexander Ford President, Myriad Genetic Laboratories | 499.2K | — | 1.95M | — | 296.5K | 11.0K | 2.76M | 70.78% | ↗ |
| 61 | 2018 | R. Bryan Riggsbee Chief Financial Officer and Treasurer; Interim President and Chief Executive Officer | 432.0K | — | 1.95M | — | 254.0K | 5.4K | 2.65M | 73.87% | ↗ |
| 62 | 2018 | R. Bryan Riggsbee Chief Financial Officer and Treasurer | 432.0K | — | 1.95M | — | 254.0K | 5.4K | 2.65M | 73.87% | ↗ |
| 63 | 2018 | R. Bryan Riggsbee Chief Financial Officer | 432.0K | — | 1.95M | — | 254.0K | 5.4K | 2.65M | 73.87% | ↗ |
| 64 | 2018 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 493.8K | — | 1.63M | — | 244.4K | 11.0K | 2.38M | 68.49% | ↗ |
| 65 | 2018 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 493.8K | — | 1.63M | — | 244.4K | 11.0K | 2.38M | 68.49% | ↗ |
| 66 | 2018 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 493.8K | — | 1.63M | — | 234.5K | 11.0K | 2.37M | 68.78% | ↗ |
| 67 | 2018 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 493.8K | — | 1.63M | — | 234.5K | 11.0K | 2.37M | 68.78% | ↗ |
| 68 | 2017 | Mark C. Capone President and Chief Executive Officer and Director | 852.0K | 307.00 | 3.61M | — | 741.2K | 10.8K | 5.22M | 69.25% | ↗ |
| 69 | 2017 | Mark C. Capone President and Chief Executive Officer* | 852.0K | 307.00 | 3.61M | — | 741.2K | 10.8K | 5.22M | 69.25% | ↗ |
| 70 | 2017 | Alexander Ford President, Myriad Womens Health, Inc. | 499.2K | 307.00 | 1.31M | — | 245.6K | 10.8K | 2.07M | 63.48% | ↗ |
| 71 | 2017 | Alexander Ford President, Myriad Womens Health, Inc. | 499.2K | 307.00 | 1.31M | — | 245.6K | 10.8K | 2.07M | 63.48% | ↗ |
| 72 | 2017 | Alexander Ford President, Myriad Genetic Laboratories | 499.2K | 307.00 | 1.31M | — | 245.6K | 10.8K | 2.07M | 63.48% | ↗ |
| 73 | 2017 | R. Bryan Riggsbee Chief Financial Officer and Treasurer | 432.0K | 307.00 | 1.31M | — | 230.7K | 8.2K | 1.99M | 66.19% | ↗ |
| 74 | 2017 | R. Bryan Riggsbee Chief Financial Officer | 432.0K | 307.00 | 1.31M | — | 230.7K | 8.2K | 1.99M | 66.19% | ↗ |
| 75 | 2017 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 493.8K | 307.00 | 1.10M | — | 222.2K | 10.9K | 1.82M | 60.09% | ↗ |
| 76 | 2017 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 493.8K | 307.00 | 1.10M | — | 222.2K | 10.9K | 1.82M | 60.09% | ↗ |
| 77 | 2017 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 493.8K | 307.00 | 1.10M | — | 214.8K | 11.0K | 1.81M | 60.34% | ↗ |
| 78 | 2016 | Mark C. Capone President and Chief Executive Officer* | 800.0K | 512.00 | 3.36M | — | 727.2K | 11.0K | 4.90M | 68.60% | ↗ |
| 79 | 2016 | Bernard F. Tobin | 412.0K | 192.1K | 2.12M | — | — | 11.4K | 2.73M | 77.49% | ↗ |
| 80 | 2016 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 479.4K | 512.00 | 1.99M | — | 215.7K | 11.3K | 2.69M | 73.75% | ↗ |
| 81 | 2016 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 479.4K | 512.00 | 1.93M | — | 218.1K | 10.8K | 2.63M | 73.09% | ↗ |
| 82 | 2016 | R. Bryan Riggsbee Chief Financial Officer | 400.0K | 512.00 | 2.04M | — | 180.0K | 10.0K | 2.63M | 77.53% | ↗ |
| 83 | 2015 | Peter D. Meldrum President and Chief Executive Officer* | 1.03M | 762.8K | 9.14M | 10.99M | 98.0K | 1.33M | 23.36M | 86.19% | ↗ |
| 84 | 2015 | James S. Evans Chief Financial Officer and Treasurer* | 163.3K | — | 2.67M | 3.07M | — | 490.0K | 6.39M | 89.77% | ↗ |
| 85 | 2015 | Mark C. Capone President and Chief Executive Officer* | 600.0K | 614.00 | 4.19M | — | 390.1K | 10.2K | 5.19M | 80.73% | ↗ |
| 86 | 2015 | Mark C. Capone President, Myriad Genetic Laboratories, Inc.* | 600.0K | 333.6K | 4.19M | — | 57.1K | 10.2K | 5.19M | 80.73% | ↗ |
| 87 | 2015 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 470.0K | 174.5K | 2.48M | — | 33.5K | 10.1K | 3.17M | 78.26% | ↗ |
| 88 | 2015 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 470.0K | 614.00 | 2.40M | — | 207.4K | 10.5K | 3.09M | 77.72% | ↗ |
| 89 | 2015 | R. Bryan Riggsbee Chief Financial Officer | 265.6K | 129.5K | 1.05M | — | — | 119.6K | 1.57M | 67.12% | ↗ |
| 90 | 2015 | R. Bryan Riggsbee Chief Financial Officer | 265.6K | 129.5K | 1.05M | — | — | 119.6K | 1.57M | 67.12% | ↗ |
| 91 | 2014 | Peter D. Meldrum President and Chief Executive Officer* | 996.2K | 819.00 | — | 5.84M | 1.29M | 10.2K | 8.14M | 71.74% | ↗ |
| 92 | 2014 | Mark C. Capone President, Myriad Genetic Laboratories, Inc.* | 567.2K | 819.00 | — | 3.38M | 552.0K | 10.2K | 4.51M | 74.95% | ↗ |
| 93 | 2014 | Mark C. Capone President and Chief Executive Officer* | 567.2K | 819.00 | — | 3.38M | 552.0K | 10.2K | 4.51M | 74.95% | ↗ |
| 94 | 2014 | James S. Evans Chief Financial Officer and Treasurer* | 476.2K | 340.8K | — | 2.15M | — | 11.2K | 2.98M | 72.21% | ↗ |
| 95 | 2014 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 457.2K | 276.8K | — | 1.95M | — | 10.5K | 2.69M | 72.34% | ↗ |
| 96 | 2014 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 450.8K | 282.8K | — | 1.84M | — | 10.7K | 2.59M | 71.25% | ↗ |
| 97 | 2014 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | — | — | — | — | — | — | — | — | ↗ |
| 98 | 2014 | James S. Evans Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 99 | 2014 | Peter D. Meldrum President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2014 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 101 | 2013 | Peter D. Meldrum President and Chief Executive Officer* | 956.1K | 5.8K | — | 5.20M | 1.24M | 10.2K | 7.41M | 70.14% | ↗ |
| 102 | 2013 | Mark C. Capone President, Myriad Genetic Laboratories, Inc.* | 546.1K | 505.8K | — | 3.00M | — | 10.3K | 4.06M | 73.85% | ↗ |
| 103 | 2013 | James S. Evans Chief Financial Officer and Treasurer | 459.1K | 327.8K | — | 1.90M | — | 9.7K | 2.70M | 70.46% | ↗ |
| 104 | 2013 | James S. Evans Chief Financial Officer and Treasurer* | 459.1K | 327.8K | — | 1.90M | — | 9.7K | 2.70M | 70.46% | ↗ |
| 105 | 2013 | Richard M. Marsh, Esq. Executive VP, General Counsel Secretary | 443.1K | 273.8K | — | 1.80M | — | 10.4K | 2.53M | 71.22% | ↗ |
| 106 | 2013 | James S. Evans Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 107 | 2013 | Peter D. Meldrum President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 108 | 2013 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | — | — | — | — | — | — | — | — | ↗ |
| 109 | 2013 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 110 | 2013 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 111 | 2012 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 420.8K | 244.8K | — | 1.21M | — | 10.4K | 1.88M | 64.11% | ↗ |
| 112 | 2012 | Peter D. Meldrum President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 113 | 2012 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 114 | 2012 | James S. Evans Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 115 | 2012 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | — | — | — | — | — | — | — | — | ↗ |
| 116 | 2011 | Peter D. Meldrum President and Chief Executive Officer | 870.5K | 956.3K | — | 3.03M | — | 9.9K | 4.87M | 62.26% | ↗ |
| 117 | 2011 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | 455.5K | 334.8K | — | 1.49M | — | 8.3K | 2.29M | 65.06% | ↗ |
| 118 | 2011 | James S. Evans Chief Financial Officer and Treasurer | 420.5K | 251.8K | — | 1.19M | — | 8.3K | 1.87M | 63.54% | ↗ |
| 119 | 2011 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 404.5K | 227.8K | — | 1.12M | — | 10.2K | 1.76M | 63.56% | ↗ |
| 120 | 2011 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 395.5K | 213.8K | — | 989.2K | — | 10.6K | 1.61M | 61.47% | ↗ |
| 121 | 2010 | Peter D. Meldrum President and Chief Executive Officer | 832.6K | 649.7K | — | 3.81M | — | 10.5K | 5.30M | 71.83% | ↗ |
| 122 | 2010 | James S. Evans Chief Financial Officer and Treasurer | 400.6K | 172.7K | — | 1.61M | — | 8.8K | 2.20M | 73.50% | ↗ |
| 123 | 2010 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 385.6K | 154.7K | — | 1.46M | — | 10.3K | 2.01M | 72.56% | ↗ |
| 124 | 2010 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | 396.6K | 178.7K | — | 1.36M | — | 8.8K | 1.95M | 70.01% | ↗ |
| 125 | 2010 | James S. Evans Chief Financial Officer and Treasurer Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 352.2K | 150.7K | — | 1.05M | — | 12.5K | 1.57M | 67.13% | ↗ |
| 126 | 2010 | Jerry S. Lanchbury, Ph.D. Chief Scientific Officer | 352.2K | 150.7K | — | 1.05M | — | 12.5K | 1.57M | 67.13% | ↗ |
| 127 | 2009 | Mark C. Capone President, Myriad Genetic Laboratories, Inc. | 361.5K | 210.8K | — | 2.67M | — | 8.5K | 3.25M | 82.13% | ↗ |
| 128 | 2009 | James S. Evans Chief Financial Officer and Treasurer | 375.6K | 265.8K | — | 2.57M | — | 9.1K | 3.22M | 79.78% | ↗ |
| 129 | 2009 | Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 360.6K | 210.8K | — | 2.39M | — | 8.5K | 2.97M | 80.48% | ↗ |
| 130 | 2009 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. Richard M. Marsh, Esq. Executive Vice President, General Counsel and Secretary | 360.6K | 210.8K | — | 1.02M | — | 8.5K | 1.60M | 63.79% | ↗ |
| 131 | 2009 | Peter D. Meldrum President and Chief Executive Officer Mark C. Capone Chief Operating Officer, Myriad Genetic Laboratories, Inc. | 361.5K | 210.8K | — | 979.4K | — | 8.5K | 1.56M | 62.77% | ↗ |
| 132 | 2008 | James S. Evans Chief Financial Officer | 278.2K | 165.8K | — | 381.3K | — | 9.6K | 834.9K | 45.67% | ↗ |
| 133 | 2007 | Peter D. Meldrum President and Chief Executive Officer | 677.0K | 550.8K | — | 428.5K | — | 9.1K | 1.67M | 25.73% | ↗ |
| 134 | 2007 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 465.5K | 350.8K | — | 378.3K | — | 9.1K | 1.20M | 31.43% | ↗ |
| 135 | 2007 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 465.5K | 300.8K | — | 378.3K | — | 9.4K | 1.15M | 32.78% | ↗ |
| 136 | 2007 | Jay M. Moyes Chief Financial Officer | 355.5K | 220.8K | — | 352.6K | — | 9.5K | 938.4K | 37.58% | ↗ |
| 137 | 2007 | Mark H. Skolnick Chief Scientific Officer | 377.5K | 150.8K | — | 279.4K | — | 9.3K | 816.9K | 34.20% | ↗ |
| 138 | 2006 | Peter D. Meldrum President and Chief Executive Officer | 615.5K | 339.0K | — | 81.0K | — | 8.3K | 962.7K | 8.41% | ↗ |
| 139 | 2006 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 424.5K | 200.7K | — | 72.0K | — | 12.6K | 637.8K | 11.29% | ↗ |
| 140 | 2006 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 424.5K | 200.7K | — | 72.0K | — | 8.8K | 634.0K | 11.36% | ↗ |
| 141 | 2006 | Jay M. Moyes Chief Financial Officer | 327.0K | 160.7K | — | 67.0K | — | 8.9K | 496.6K | 13.49% | ↗ |
| 142 | 2006 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 342.0K | 130.7K | — | 51.0K | — | 9.1K | 481.9K | 10.58% | ↗ |
| 143 | 2005 | Peter D. Meldrum President and Chief Executive Officer | 580.5K | 290.6K | — | 95.0K | — | 9.1K | 880.2K | 10.79% | ↗ |
| 144 | 2005 | Peter D. Meldrum President and Chief Executive Officer | 580.5K | 290.6K | — | 95.0K | — | 9.1K | 880.2K | 10.79% | ↗ |
| 145 | 2005 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 400.5K | 170.6K | — | 85.0K | — | 8.5K | 579.6K | 14.67% | ↗ |
| 146 | 2005 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 400.5K | 170.6K | — | 85.0K | — | 8.5K | 579.6K | 14.67% | ↗ |
| 147 | 2005 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 400.5K | 170.6K | — | 85.0K | — | 4.8K | 575.8K | 14.76% | ↗ |
| 148 | 2005 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 400.5K | 170.6K | — | 85.0K | — | 4.8K | 575.8K | 14.76% | ↗ |
| 149 | 2005 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 326.7K | 105.6K | — | 60.0K | — | 9.9K | 442.2K | 13.57% | ↗ |
| 150 | 2005 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 326.7K | 105.6K | — | 60.0K | — | 9.9K | 442.2K | 13.57% | ↗ |
| 151 | 2005 | Jay M. Moyes Chief Financial Officer | 308.5K | 100.6K | — | 75.0K | — | 8.9K | 418.0K | 17.94% | ↗ |
| 152 | 2005 | Jay M. Moyes Chief Financial Officer | 308.5K | 100.6K | — | 75.0K | — | 8.9K | 418.0K | 17.94% | ↗ |
| 153 | 2004 | Peter D. Meldrum President and Chief Executive Officer | 520.5K | 240.5K | — | 75.0K | — | 8.1K | 769.1K | 9.75% | ↗ |
| 154 | 2004 | Peter D. Meldrum President and Chief Executive Officer | 520.5K | 240.5K | — | 75.0K | — | 8.1K | 769.1K | 9.75% | ↗ |
| 155 | 2004 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 370.5K | 157.5K | — | 65.0K | — | 6.7K | 534.7K | 12.16% | ↗ |
| 156 | 2004 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 370.5K | 157.5K | — | 65.0K | — | 6.7K | 534.7K | 12.16% | ↗ |
| 157 | 2004 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 370.5K | 152.5K | — | 65.0K | — | 8.1K | 531.1K | 12.24% | ↗ |
| 158 | 2004 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 370.5K | 152.5K | — | 65.0K | — | 8.1K | 531.1K | 12.24% | ↗ |
| 159 | 2004 | Jay M. Moyes Chief Financial Officer | 270.5K | 120.5K | — | 70.0K | — | 6.5K | 397.5K | 17.61% | ↗ |
| 160 | 2004 | Jay M. Moyes Chief Financial Officer | 270.5K | 120.5K | — | 70.0K | — | 6.5K | 397.5K | 17.61% | ↗ |
| 161 | 2004 | Jay M. Moyes Vice President of Finance, Chief Financial Officer | 270.5K | 120.5K | — | 70.0K | — | 6.5K | 397.5K | 17.61% | ↗ |
| 162 | 2004 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 273.2K | 105.5K | — | 65.0K | — | 5.9K | 384.6K | 16.90% | ↗ |
| 163 | 2004 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 273.2K | 105.5K | — | 65.0K | — | 5.9K | 384.6K | 16.90% | ↗ |
| 164 | 2003 | Peter D. Meldrum President and Chief Executive Officer | 455.5K | 150.5K | — | 70.0K | — | 10.3K | 616.3K | 11.36% | ↗ |
| 165 | 2003 | Peter D. Meldrum President and Chief Executive Officer | 455.5K | 150.5K | — | 70.0K | — | 10.3K | 616.3K | 11.36% | ↗ |
| 166 | 2003 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 323.4K | 90.5K | — | 55.0K | — | 6.3K | 420.2K | 13.09% | ↗ |
| 167 | 2003 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 323.4K | 90.5K | — | 55.0K | — | 6.3K | 420.2K | 13.09% | ↗ |
| 168 | 2003 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 323.4K | 90.5K | — | 55.0K | — | 6.3K | 420.2K | 13.09% | ↗ |
| 169 | 2003 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 323.4K | 90.5K | — | 55.0K | — | 6.3K | 420.2K | 13.09% | ↗ |
| 170 | 2003 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 278.8K | 90.5K | — | 60.0K | — | 6.1K | 375.4K | 15.98% | ↗ |
| 171 | 2003 | Jay M. Moyes Chief Financial Officer | 249.7K | 80.5K | — | 60.0K | — | 6.5K | 336.7K | 17.82% | ↗ |
| 172 | 2003 | Jay M. Moyes Vice President of Finance, Chief Financial Officer | 249.7K | 80.5K | — | 60.0K | — | 6.5K | 336.7K | 17.82% | ↗ |
| 173 | 2002 | Peter D. Meldrum President and Chief Executive Officer | 385.5K | 131.0K | — | 35.0K | — | 1.4K | 517.9K | 6.76% | ↗ |
| 174 | 2002 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 286.5K | 81.0K | — | 30.0K | — | 5.3K | 372.9K | 8.05% | ↗ |
| 175 | 2002 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 270.5K | 81.0K | — | 30.0K | — | 5.6K | 357.2K | 8.40% | ↗ |
| 176 | 2002 | Jay M. Moyes Vice President of Finance, Chief Financial Officer | 208.0K | 61.0K | — | 25.0K | — | 5.7K | 274.7K | 9.10% | ↗ |
| 177 | 2002 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | 185.2K | 66.0K | — | 25.0K | — | 3.3K | 254.5K | 9.82% | ↗ |
| 178 | 2002 | Christopher L. Wight Vice President, General Counsel | 185.4K | 1.0K | — | 10.0K | — | 3.1K | 189.6K | 5.28% | ↗ |
| 179 | 2001 | Christopher L. Wight Vice President, General Counsel | 174.5K | 30.8K | — | 10.0K | — | 5.5K | 210.7K | 4.75% | ↗ |
| 180 | 2001 | Jay M. Moyes Vice President of Finance, Chief Financial Officer | — | — | — | — | — | 5.8K | 5.8K | 0.00% | ↗ |
| 181 | 2001 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | — | — | — | — | — | 5.8K | 5.8K | 0.00% | ↗ |
| 182 | 2001 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | — | — | — | — | — | 5.6K | 5.6K | 0.00% | ↗ |
| 183 | 2001 | Peter D. Meldrum President and Chief Executive Officer | — | — | — | — | — | 5.6K | 5.6K | 0.00% | ↗ |
| 184 | 2001 | Mark H. Skolnick, Ph.D. Chief Scientific Officer | — | — | — | — | — | 227.00 | 227.00 | 0.00% | ↗ |
| 185 | 2000 | Peter D. Meldrum President and Chief Executive Officer | 320.5K | 100.5K | — | 100.0K | — | 5.1K | 426.1K | 23.47% | ↗ |
| 186 | 2000 | Gregory C. Critchfield, M.D. President, Myriad Genetic Laboratories, Inc. | 240.5K | 84.5K | — | 80.0K | — | 5.2K | 330.2K | 24.23% | ↗ |
| 187 | 2000 | Adrian N. Hobden, Ph.D. President, Myriad Pharmaceuticals, Inc. | 215.6K | 75.5K | — | 80.0K | — | 5.3K | 296.3K | 27.00% | ↗ |
| 188 | 2000 | Jay M. Moyes Vice President of Finance, Chief Financial Officer | 168.4K | 60.5K | — | 60.0K | — | 5.2K | 234.2K | 25.62% | ↗ |
| 189 | 2000 | Christopher L. Wight Vice President, General Counsel | 165.4K | 35.5K | — | 15.0K | — | 5.3K | 206.2K | 7.27% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Samraat S. Raha | President, Chief Executive Officer & Director | 2M | male |
| Paul J. Diaz | Consultant | 2M | male |
| Brian Donnelly | Chief Commercial Officer | 1M | male |
| Mark S. Verratti | Chief Operating Officer | 1M | male |
| Benjamin R. Wheeler | Chief Financial Officer & Principal Accounting Officer | 748.7K | male |
| Dale Muzzey | Chief Scientific Officer | 741.9K | — |
| Kevin Richard Haas | Chief Technology Officer | 580.4K | — |
| Thomas Slavin | Chief Medical Officer | — | — |
| Jennifer L. Fox | Chief Legal Officer | — | female |
| Matthew Scalo | Senior Vice President of Investor Relations | — | male |
| Patrick Burke | Executive Vice President of Innovation & Strategic Partnerships | — | — |
| Shereen Solaiman | Chief People Officer | — | female |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MYGN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
